Table 1.
Study | Study type | Country | Patient selection period | Tumour type | Tumour size | Pre-treatment examinations | RFA technique | Evaluation of post-treatment effect of RFA |
Follow-up examination |
|||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Method | Contrast | Time | Number (patients/lesions) | Age (years) | Method | Time | ||||||||
Choi et al 200312 | R | Republic of Korea | May 2000–December 2001 | Nodular HCC | 1.3–4.8 cm | Ultrasound | Real-time ultrasound-guided PRFA | CEUS | SH U 508A | <24 h (14–20 h) | 75/81 | 57 (31–72) | CT | 12–32 months |
Dill-Macky et al 200613 | P | Canada | December 2002–February 2004 | HCC of hypervascular lesions | 1.5–3.7 cm | Multiphasic CT/dynamic MRI | Sonographic- or CT-guided RFA | CEUS | SH U 508A | <1 h (15–60 min) | 19/22 | 43–83 | Multiphasic CT, gadolinium-enhanced dynamic MRI | 3–13 months |
Du et al 201514 | P | China | September 2011–January 2013 | HCC | 0.8–2.9 cm | Dynamic contrast-enhanced MRI | Conventional greyscale ultrasound, CEUS-guided PRFA | CEUS | SonoVue | <1 h (20–30 min) | 63/78 | 55 ± 7 (41–67) | Contrast-enhanced MRI | 11–29 months |
Inoue et al 201315 | R | Japan | January 2007–December 2011 | HCC | 16.5 ± 7.1 mm | Dynamic CT | Ultrasound-guided PRFA | CEUS | Sonazoid™ | 1–3 days | 70/86 | 70.7 ± 7.1 | Dynamic CT | 873 ± 426 days |
Kisaka et al 200622 | R | Japan | March 2004–August 2004 | HCC | 1.0–2.9 cm | Ultrasound | Ultrasound-guided PRFA | CEUS with VUS | SH U 508A | 3 days | 22/26 | 68.6 ± 8.08 | CECT | – |
Kisaka et al 201016 | P | Japan | May 2005–August 2006 | HCC | 17.0 ± 6.5 mm | CT | Ultrasound-guided PRFA | CEUS with VUS | SH U 508A | 3 days | 25/25 | 67.0 ± 8.9 | Dynamic CT | 1 year |
Luo et al 201017 | P | Japan | February 2007–November 2007 | HCC | 22 mm (10–30 mm) | 3D CECT/CEUS | Real-time ultrasound-guided PRFA | 3D CEUS | Sonazoid | 1 day | 63/63 | 70 (53–80) | 3D CECT | 3–21 months |
Nishigaki et al 201511 | R | Japan | January 2007–June 2010 | HCC | 16.7 ± 6.1 mm | CT/MRI | CEUS-guided PRFA | CEUS | Sonazoid | 3 h | 87/87 | 71 ± 9 | 1140 days | |
Numata et al 201223 | P | Japan | June 2009–December 2012 | HCC | 16 mm (10–30 mm) | CECT, fusion imaging combined with CEUS | Real-time ultrasound-guided RFA | Fusion imaging-CEUS | Sonazoid | 1 day | 67/80 | 73 (51–84) | CECT | 6–24 months |
Ricci et al 200918 | P | – | January 2001–May 2004 | HCC | 3.7 ± 1.1 cm (2.6–4.8 cm) | Real time contrast-enhanced examination, helical CT | Real-time sonography-guided RFA | Low-mechanical index CEUS | SonoVue | 1 month | 100/100 | 62–76 | CT | – |
Shimizu et al 200419 | P | Japan | October 2000–June 2001 | HCC | 10–60 mm | ADI, CECT | RFA | CEUS | SH U 508A | 1 day | 40/64 | 66.3 (50–85) | Dynamic CT | – |
Zheng et al 201320 | P | China | May 2007–March 2011 | HCC | 2.4 cm (0.6–5.7 cm) | CECT, CEUS | Ultrasound-guided PRFA | CEUS | SonoVue | 1 month | 141/221 | 53.4 (27–81) | CECT, CEUS | 1–31 months |
3D, three-dimensional; ADI, agent detection imaging; CECT, contrast-enhanced CT; CEUS, contrast-enhanced ultrasonography; HCC, hepatocellular carcinomas; P, prospective; PRFA, percutaneous radiofrequency ablation; R, retrospective; RFA, radiofrequency ablation; VUS, virtual ultrasonography.